NasdaqGS - Nasdaq Real Time Price USD

AlloVir, Inc. (ALVR)

0.7960 +0.0330 (+4.33%)
As of 2:45 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David L. Hallal Executive Chairman of the Board 254.38k -- 1966
Dr. Diana M. Brainard M.D. CEO & Director 978.99k -- 1972
Mr. Vikas Sinha C.A., CPA, M.B.A. President, CFO & Director 536.21k -- 1963
Mr. Edward Miller J.D. General Counsel & Secretary 618.39k -- 1965
Mr. Brett R. Hagen Chief Accounting Officer -- -- 1973
Mr. Dana M. Alexander Senior Vice President of Technical Operations -- -- 1976
Dr. Ann M. Leen Ph.D. Chief Scientific Officer -- -- 1978
Mr. Ugo Capolino Perlingieri Head & GM of Europe and Middle East Operations -- -- --
Ms. Cintia Piccina Pharm.D. Chief Commercial Officer -- -- 1974

AlloVir, Inc.

1100 Winter Street
Waltham, MA 02451
United States
617 433 2605 https://www.allovir.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
112

Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Corporate Governance

AlloVir, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
AlloVir, Inc. Earnings Call

Related Tickers

SYBX Synlogic, Inc.
1.9100
+4.95%
 
PRTC.L PureTech Health plc
213.00
+3.65%
 
GLTO Galecto, Inc.
0.6895
+1.25%
 
RPHM Reneo Pharmaceuticals, Inc.
1.6850
-0.30%
 
CTMX CytomX Therapeutics, Inc.
1.6800
+0.60%
 
ASMB Assembly Biosciences, Inc.
13.10
-0.91%
 
PULM Pulmatrix, Inc.
2.0201
+0.50%
 
NXTC NextCure, Inc.
1.5500
-3.73%
 
TIL Instil Bio, Inc.
10.78
+0.65%
 
EIGRQ Eiger BioPharmaceuticals, Inc.
3.7600
-6.00%